In just six months, the world’s largest randomized control trial on COVID-19 therapy has produced conclusive evidence on the effectiveness of reabsorbed drugs for the treatment of COVID-19.
The interim results of the Solidarity Therapeutics Trial, coordinated by the World Health Organization, show that there has been little or no impact on the hospital course between 28-day mortality or COVID-19 in hospitalized patients.
The study, which spans more than 30 countries, looked at the effects of these treatments on overall mortality, initiation of ventilation, and duration of hospitalized patients. Other uses of drugs, for example for the treatment or prevention of patients in the community, should be investigated using various tests.
The progress achieved by the Solidarity Therapeutics Trial suggests that large international trials are possible even during an epidemic, and promises to quickly and reliably answer important public health questions related to medical topics.
The test results are subject to review for publication in a medical journal and uploaded as a prepair to medRxiv, available at this link: https://www.medrxiv.org/content/10.1101/2020.10.15.20209817v1
The global platform of Solidarity Trials is set to rapidly evaluate new treatment options, with around 500 hospitals open as trial sites.
New antiviral drugs, immunomodulators, and anti-SARS COV-2 monoclonal antibodies are now being considered for evaluation.